Business Weekly - Cambridge, UK

Abcam CEO, Jonathan Milner

Its shares shot 29.5p (7.63 per cent) higher to 416p on news that sales growth, so far, in the second half of the financial year has been particularly strong as a result of higher volumes, improved pricing and beneficial exchange rate movements, particularly in the Euro/£ rate.

Sales are now expected to be ahead of market expectations and the outlook for the profit for the full year to June 30 has improved significantly, the company reported.

Jonathan Milner, Abcam's  CEO, said: "We have been particularly pleased by the momentum in our sales growth across all of our geographies.

“This momentum is a reflection of the growth in the research antibody market, of the strength of the Abcam brand and of our leadership in the selection of antibodies of particular scientific interest.”

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo.

It produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world.

The company’s vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable.

Abcam now has an online catalogue of approximately 42,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the company. The company employs 176 staff in its three operating companies.

TrackBack URI for this entry

Comments (0)

Subscribe to this comment's feed